Discussion
fits, cancer, NMIBC
CANCER, RECURRENCE
The major clinical challenges in NMIBC are the high rate of recurrence and the lack of a more precise delivery of care. Despite the molecular heterogeneity of NMIBC, all patients are treated according to the same protocol and followed by invasive and potentially harmful procedures.Therefore, we aim to precise the treatment of NMIBC thus making the therapy more effective.We believe that a more precise adjuvant treatment of NMIBC patients will reduce the risk of cancer recurrence and that drug screens in PDO may be a promising strategy to precise drug selection for intravesical instillation. The establishment of our protocols as part of clinical trials will allow us to investigate novel compounds for the intravesical treatment of NMIBC patients. Our in-vitro experiments may suggest other compounds for intravesical instillation that have not yet been investigated. In the future, we aim to conduct clinical multicenter trials with an increased sample size, a broader panel of compounds and a focus on the reduction of cancer recurrence by precision delivery of care.NMIBC is the costliest cancer on a per patient treatment basis. All patients are treated in a “one size fits all” manner and the workup at diagnostics and during follow-up is invasive and may be harmful. The success of this project will help to precise the treatment of patients with intermediate-risk NMIBC. Further, the establishment of our pipeline, will allow an effective and biologically driven investigation of novel compounds for intravesical instillation therapies.